Lv4
740 积分 2024-10-16 加入
Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment
6天前
已完结
Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
6天前
已完结
Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial
6天前
已完结
Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose‐escalation phase 1 study
6天前
已完结
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
6天前
已完结
Advancing siRNA Therapeutics with Pharmacometrics: A Review of Modeling Approaches and Clinical Applications
12天前
已完结
Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS
1个月前
已完结
Context-of-use–Guided Development and Validation of a Transthyretin Immunoassay: A Framework for Biomarker Assay Design
1个月前
已完结
Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran
1个月前
已完结
皖公网安备34019202002308
